# NCT05680922 (NCT05680922)

> DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05680922
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Legend Biotech USA Inc
- Conditions: Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions: LB2102
- Enrollment: 41
- Primary outcome: To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE)
- Primary outcome: To further characterize the safety and tolerability of LB2102 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05680922